We're taking a closer look at Legend Biotech today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -2.5% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
-
Legend Biotech has moved 49.0% over the last year compared to 15.0% for the S&P 500 -- a difference of 34.0%
-
LEGN has an average analyst rating of buy and is -26.3% away from its mean target price of $88.18 per share
-
Its trailing 12 month earnings per share (EPS) is $-3.11
-
Legend Biotech has a trailing 12 month Price to Earnings (P/E) ratio of -20.9 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-2.39 and its forward P/E ratio is -27.2
-
The company has a Price to Book (P/B) ratio of 8.38 in contrast to the S&P 500's average ratio of 2.95
-
Legend Biotech is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
Legend Biotech has on average reported free cash flows of $-162293500.0 over the last four years, during which time they have grown by an an average of -0.0%